Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Interactive Features

Test Your Knowledge
Quiz: Is Neutropenia a Prognostic Factor for OS in NSCLC?
11/11/2020
True or false: Moderate neutropenia levels predict improved OS in NSCLC after gem-carbo therapy.
True or false: Moderate neutropenia levels predict improved OS in NSCLC after gem-carbo therapy.
True or false: Moderate...
11/11/2020
Oncology
lungs grey
Test Your Knowledge
Quiz: How Have Advances in Lung Cancer Treatment Affected NSCLC Mortality Rates?
09/16/2020
True or False: Population-based death rates from NSCLC in the United States dramatically declined between 2013 and 2016.
True or False: Population-based death rates from NSCLC in the United States dramatically declined between 2013 and 2016.
True or False: Population-based...
09/16/2020
Oncology

Advertisement

lungs grey
Test Your Knowledge
Quiz: How Have Advances in Lung Cancer Treatment Affected NSCLC Mortality Rates?
09/16/2020
True or False: Population-based death rates from NSCLC in the United States dramatically declined between 2013 and 2016.
True or False: Population-based death rates from NSCLC in the United States dramatically declined between 2013 and 2016.
True or False: Population-based...
09/16/2020
Oncology
Test Your Knowledge
Quiz: Was a Liquid Biopsy Tool Recently FDA Approved to Identify ROS-mutated NSCLC?
09/15/2020
True or false: A liquid biopsy companion diagnostic was recently FDA-approved to help identify ROS-mutated NSCLC.
True or false: A liquid biopsy companion diagnostic was recently FDA-approved to help identify ROS-mutated NSCLC.
True or false: A liquid biopsy...
09/15/2020
Oncology
Test Your Knowledge
Quiz: Can a Deep Learning Model Predict Therapy Benefit in NSCLC?
08/31/2020
True or False: A deep learning survival neural network model displays potential benefit in prognostic evaluation and treatment recommendations, with respect to lung cancer–specific survival.
True or False: A deep learning survival neural network model displays potential benefit in prognostic evaluation and treatment recommendations, with respect to lung cancer–specific survival.
True or False: A deep learning...
08/31/2020
Oncology

Advertisement

Test Your Knowledge
Quiz: Tazemetostat Monotherapy for Relapsed/Refractory Malignant Mesothelioma
08/13/2020
True or False: Tazemetostat is well-tolerated and yields anti-tumor activity in patients with BAP1-deficient relapsed or refractory malignant mesothelioma.
True or False: Tazemetostat is well-tolerated and yields anti-tumor activity in patients with BAP1-deficient relapsed or refractory malignant mesothelioma.
True or False: Tazemetostat is...
08/13/2020
Oncology
Test Your Knowledge
Quiz: Which Combination Benefits Patients with Mesothelin-Expressing Solid Tumors?
08/06/2020
Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?
Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?
Which combination yielded...
08/06/2020
Oncology
Test Your Knowledge
Quiz: Is Nivolumab-Ipilimumab Plus Chemo FDA-Approved for mNSCLC?
07/17/2020
True or false: The FDA approved nivolumab and ipilimumab along with platinum-doublet chemotherapy for the frontline treatment of patients with metastatic or relapsed NSCLC, based on results from the CHECKMATE-9LA trial.
True or false: The FDA approved nivolumab and ipilimumab along with platinum-doublet chemotherapy for the frontline treatment of patients with metastatic or relapsed NSCLC, based on results from the CHECKMATE-9LA trial.
True or false: The FDA approved...
07/17/2020
Oncology

Advertisement

Test Your Knowledge
Quiz: Pembrolizumab Plus Docetaxel for Advanced, Pretreated NSCLC
04/29/2020
True or False: In a phase 2 clinical trial, pembrolizumab plus docetaxel did not improve overall response rates and progression-free survival in pretreated patients with NSCLC.
True or False: In a phase 2 clinical trial, pembrolizumab plus docetaxel did not improve overall response rates and progression-free survival in pretreated patients with NSCLC.
True or False: In a phase 2...
04/29/2020
Oncology
Test Your Knowledge
Quiz: A Potential Combo Therapy for EGFR-Positive, MET-Amplified NSCLC
04/13/2020
True or False: Researchers posit osimertinib plus savolitinib as a potential combo therapy for MET-amplified, EGFR-positive, advanced NSCLC that progressed with EGFR TKIs.
True or False: Researchers posit osimertinib plus savolitinib as a potential combo therapy for MET-amplified, EGFR-positive, advanced NSCLC that progressed with EGFR TKIs.
True or False: Researchers posit...
04/13/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use